Trials / Completed
CompletedNCT00004667
Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (planned)
- Sponsor
- National Center for Research Resources (NCRR) · NIH
- Sex
- All
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease. II. Assess the safety of von Willebrand factor in these patients.
Detailed description
PROTOCOL OUTLINE: Patients receive 1 dose of von Willebrand factor concentrate. Timed blood studies are performed for the next 96 hours. Patients are followed every 2 weeks for 16 weeks, and at 24, 36, and 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | von Willebrand factor |
Timeline
- Start date
- 1993-10-01
- First posted
- 2000-02-25
- Last updated
- 2005-06-24
Source: ClinicalTrials.gov record NCT00004667. Inclusion in this directory is not an endorsement.